Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis

BACKGROUND AND AIMS: Esophageal variceal bleeding is a life-threatening complication of cirrhosis, yet current risk stratification targets portal hypertension stage and endoscopic stigmata instead of short-term bleeding probability. We evaluated whether a simple score built from routinely available variables could stratify 1-year esophageal variceal bleeding risk. METHODS: We developed and internally validated two multivariable logistic models in a retrospective outcome-balanced cohort of 108 patients with esophageal varices (54 variceal bleeding, 54 no bleeding). VA-BLED BASE incorporated Child-Pugh score, normalized alanine aminotransferase, and current alcohol use. VA-BLED HISTORY additionally incorporated previous bleeding. Performance was assessed from out-of-fold predictions using discrimination, calibration, and decision curve analysis. RESULTS: VA-BLED BASE achieved an out-of-fold area under the receiver operating characteristic curve of 0.732 (95% confidence interval, 0.635-0.827), which increased to 0.798 (95% confidence interval, 0.705-0.883) when previous bleeding history was included. Both models provided net benefit across clinically plausible threshold probabilities. At an assumed annual bleeding prevalence of 10%, VA-BLED BASE generated low-, intermediate-, and high-risk zones, whereas VA-BLED HISTORY functioned primarily as a high-risk enrichment model. CONCLUSIONS: In this proof-of-concept development study, VA-BLED BASE and VA-BLED HISTORY stratified 1-year EVB risk using routinely available clinical variables and identified subgroups enriched for bleeding events. External validation in cohort-design populations is required before clinical application.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-16
DOI
https://doi.org/10.1371/journal.pone.0362884
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis

Silja Schröder, Dominic Denk, Mireen Friedrich‐Rust, Alexander Queck et al.
1 links
PLoS ONE
Liver Disease and Transplantation
article

Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis

Silja Schröder, Dominic Denk, Mireen Friedrich‐Rust, Alexander Queck, Stefan Zeuzem
article en

Abstract

BACKGROUND AND AIMS: Esophageal variceal bleeding is a life-threatening complication of cirrhosis, yet current risk stratification targets portal hypertension stage and endoscopic stigmata instead of short-term bleeding probability. We evaluated whether a simple score built from routinely available variables could stratify 1-year esophageal variceal bleeding risk. METHODS: We developed and internally validated two multivariable logistic models in a retrospective outcome-balanced cohort of 108 patients with esophageal varices (54 variceal bleeding, 54 no bleeding). VA-BLED BASE incorporated Child-Pugh score, normalized alanine aminotransferase, and current alcohol use. VA-BLED HISTORY additionally incorporated previous bleeding. Performance was assessed from out-of-fold predictions using discrimination, calibration, and decision curve analysis. RESULTS: VA-BLED BASE achieved an out-of-fold area under the receiver operating characteristic curve of 0.732 (95% confidence interval, 0.635-0.827), which increased to 0.798 (95% confidence interval, 0.705-0.883) when previous bleeding history was included. Both models provided net benefit across clinically plausible threshold probabilities. At an assumed annual bleeding prevalence of 10%, VA-BLED BASE generated low-, intermediate-, and high-risk zones, whereas VA-BLED HISTORY functioned primarily as a high-risk enrichment model. CONCLUSIONS: In this proof-of-concept development study, VA-BLED BASE and VA-BLED HISTORY stratified 1-year EVB risk using routinely available clinical variables and identified subgroups enriched for bleeding events. External validation in cohort-design populations is required before clinical application.

PLoS ONEVol. 21(11)
Goethe University Frankfurt (DE), Sanford Burnham Prebys Medical Discovery Institute (US), University of California San Diego (US), University Hospital Frankfurt (DE)
Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe
Good health and well-being
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon